Dyadic International (NASDAQ:DYAI) Earns “Buy” Rating from HC Wainwright

Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $6.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 430.97% from the stock’s current price.

Dyadic International Stock Performance

Shares of Dyadic International stock opened at $1.13 on Thursday. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.39. The stock has a market capitalization of $33.44 million, a price-to-earnings ratio of -4.91 and a beta of 0.72. The business has a 50-day moving average of $1.12 and a 200 day moving average of $1.42. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The company had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. During the same period in the prior year, the business earned ($0.06) EPS. As a group, sell-side analysts forecast that Dyadic International will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. increased its position in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 847,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.